Tolerogenic therapy

FibroBiologics Presents Preclinical Data at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Tolerogenic therapy, Regenerative medicine, Fibroblast, Apache Hadoop, Conditional sentence, Multimedia, Patient, CBC, Sensory deprivation, Government budget balance, Elective surgery, Neuron, Brain, IND, Convention center, MS, Gaylord National Resort & Convention Center, Communication, Multiple sclerosis, Safety, B cell, Wound healing, EAE, Cancer, Microsoft, Vaccine, Regulatory T cell

Multiple Sclerosis (MS), a T cell-mediated autoimmune disorder targeting the myelin sheath of the axon process of the neurons, leads to severe progressive cognitive impairment, sensory deprivation, and weakened coordination.

Key Points: 
  • Multiple Sclerosis (MS), a T cell-mediated autoimmune disorder targeting the myelin sheath of the axon process of the neurons, leads to severe progressive cognitive impairment, sensory deprivation, and weakened coordination.
  • Extensive preclinical studies of tolerogenic HDFs, which can elicit immunological tolerance, were performed in the experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis.
  • Based in Houston, FibroBiologics is a regenerative medicine company developing a pipeline of treatments for chronic diseases using fibroblast cells.
  • FibroBiologics holds 150+ US and international issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer.

Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Monday, May 2, 2022
Private Securities Litigation Reform Act, NASDAQ, GLOBE, Nanoparticle, Cell, AAV, Methylmalonic acidemia, Safety, Immune tolerance, Volunteering, Patient, Gene, Clinical trial, CD8, Human, Annual report, Degenerative disease, Society, Lists of diseases, U.S. Securities and Exchange Commission, Autoimmunity, Tolerogenic therapy, Vaccine, Mouse

These presentations demonstrate the power of Selectas immune tolerance platform, ImmTOR, in mitigating unwanted immune responses to AAV capsids and potentially enabling gene therapy re-dosing for patients with severe genetic disorders.

Key Points: 
  • These presentations demonstrate the power of Selectas immune tolerance platform, ImmTOR, in mitigating unwanted immune responses to AAV capsids and potentially enabling gene therapy re-dosing for patients with severe genetic disorders.
  • We are thrilled to present data demonstrating ImmTORs ability to inhibit anti-AAV antibody formation and potentially enable re-dosing of gene therapies.
  • Furthermore, we are pleased to showcase results indicating an evolution of our ImmTOR platform is close at hand.
  • Selecta Biosciences, Inc.is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Medical specialties, Immunology, Clinical medicine, Immune system, Cell biology, Tolerogenic dendritic cell, Dendritic cell, Regulatory T cell, Tolerogenic therapy, Protective autoimmunity

Of great interest was the association between increased numbers of T regulatory cells and therapeutic activity.

Key Points: 
  • Of great interest was the association between increased numbers of T regulatory cells and therapeutic activity.
  • Previously the Company reported that administration of T regulatory cells are capable of suppressing schizophrenia.
  • "It is incredible to contemplate that immunological reactions such as the ability of tolerogenic dendritic cells to induce T regulatory cells can be used to treated neurological diseases.
  • "Schizophrenia is a very peculiar disease which possesses numerous immunological connections," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

Selecta Biosciences Announces Frontiers in Immunology Publication Showcasing the Enhanced Hepatic Tolerogenic Potential of ImmTOR™

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Medicine, Clinical medicine, Immunology, Autoimmunity, Immune tolerance, Autoimmune disease, Liver, Sjögren syndrome, Tolerogenic therapy, Tolerogenic dendritic cell

These findings demonstrate the capability of Selectas ImmTOR platform in promoting hepatic immune tolerance, providing support for the potential of ImmTOR for the treatment of autoimmune diseases affecting the liver.

Key Points: 
  • These findings demonstrate the capability of Selectas ImmTOR platform in promoting hepatic immune tolerance, providing support for the potential of ImmTOR for the treatment of autoimmune diseases affecting the liver.
  • Liver specific autoimmune diseases result from the loss of natural immunological tolerance to hepatic autoantigens, said Carsten Brunn, Ph.D., president and chief executive officer of Selecta.
  • Altogether, this publication supports the use of ImmTOR in generating a tolerogenic hepatic environment that can combat unwanted inflammatory responses in the liver.
  • Selecta Biosciences Inc.(NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

SQZ Biotechnologies Presents Preclinical Data for their SQZ Tolerizing Antigen Carrier Platform in Antigen-Specific Immune Tolerance (ASIT) Digital Summit Invited Talk

Retrieved on: 
Wednesday, January 27, 2021
Other Health, Other Science, Pharmaceutical, Research, Oncology, Medical devices, Infectious diseases, Hospitals, Genetics, Science, Nursing, Clinical trials, Managed care, Cardiology, General Health, Biotechnology, Diabetes, Health, Immunology, Medicine, Branches of biology, Immune system, Health care, Immune tolerance, Antigen, Cell biology, Tolerogenic therapy, SQZ TACs, SQZ Biotechnologies

SQZ TACs are a red blood cell (RBC)-derived cell therapy candidate being developed as an antigen-specific immune tolerance platform.

Key Points: 
  • SQZ TACs are a red blood cell (RBC)-derived cell therapy candidate being developed as an antigen-specific immune tolerance platform.
  • This platform is designed to leverage the inherently tolerogenic physiological process of RBC clearance to generate immune tolerance against target antigens.
  • Also included in the presentation are preclinical mouse data that show:
    Specificity of SQZ TAC immune-tolerance against target antigens without broad immune suppression.
  • SQZ TACs are a red blood cell-derived cell therapy candidate being developed as an antigen-specific immune tolerance platform.

Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Retrieved on: 
Thursday, December 10, 2020
Branches of biology, Medical specialties, Clinical medicine, Immunology, Cell biology, Immune system, Tolerogenic dendritic cell, T cells, Immunotherapy, Dendritic cell, Regulatory T cell, Tolerogenic therapy

Detailed scientific analysis revealed that ImmCelz administration caused generation of T regulatory cells and tolerogenic dendritic cells.

Key Points: 
  • Detailed scientific analysis revealed that ImmCelz administration caused generation of T regulatory cells and tolerogenic dendritic cells.
  • "We are extremely enthusiastic to discover that ImmCelz, which is a personalized immunotherapy can induce similar biological processes and in this case suppress autoimmunity."
  • Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

Retrieved on: 
Wednesday, August 5, 2020
Branches of biology, Medical specialties, Immunology, Biology, Regulatory T cell, Benaroya Research Institute, Autoimmunity, Immunoglobulin E, Cell therapy, Immune system, Tolerogenic therapy

Additionally, GentiBio's platform will enable the scaled production of robust EngTregs cell therapy products that are antigen specific and tunable.

Key Points: 
  • Additionally, GentiBio's platform will enable the scaled production of robust EngTregs cell therapy products that are antigen specific and tunable.
  • "Tregs are rare cells within the immune system and current therapies that source Tregs cells from the blood stream can be costly and cumbersome.
  • "This partnership with GentiBio is an important step forward in identifying and improving novel treatments for autoimmune diseasesa key goal of the Benaroya Research Institute.
  • An internationally recognized medical research institute, BRI accelerates discovery through laboratory breakthroughs in immunology that are translated to clinical therapies.

Anokion to Present at the 3rd Antigen Specific Immune Tolerance Summit

Retrieved on: 
Wednesday, February 19, 2020
Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Immunology, Health, RTT, Autoimmune disease, Autoimmunity, Immune tolerance, Sjögren syndrome, Antigen, Tolerogenic therapy, Immunologic checkpoint

Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Stephan Kontos, Ph.D., co-founder and chief scientific officer of Anokion, will give a presentation titled, Translational & Clinical Development of Novel, Liver Targeted Immune Tolerance Therapies for Celiac Disease & Multiple Sclerosis, on Wednesday, February 26 at 5:00pm ET at the 3rd Antigen Specific Immune Tolerance Summit (ASIT 2020) in Boston.

Key Points: 
  • Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Stephan Kontos, Ph.D., co-founder and chief scientific officer of Anokion, will give a presentation titled, Translational & Clinical Development of Novel, Liver Targeted Immune Tolerance Therapies for Celiac Disease & Multiple Sclerosis, on Wednesday, February 26 at 5:00pm ET at the 3rd Antigen Specific Immune Tolerance Summit (ASIT 2020) in Boston.
  • Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance.
  • The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.
  • Anokions distinct approach leverages the companys immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.

Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation

Retrieved on: 
Thursday, September 27, 2018
Medicine, Clinical medicine, Organ transplantation, Kidney transplantation, Atypical hemolytic uremic syndrome, Tolerogenic therapy

The trials were single arm, open label studies to assess the safety and efficacy of imlifidase with either a deceased or living donor kidney.

Key Points: 
  • The trials were single arm, open label studies to assess the safety and efficacy of imlifidase with either a deceased or living donor kidney.
  • Observed frequencies of infections in the clinical studies are in line with what is expected for kidney transplantation patients in general.
  • Efficacy data reported from four Phase 2 studies have demonstrated that imlifidase rapidly and significantly reduced these DSAs, enabling transplantation.
  • Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases.